核心观点 公司持续推进"团个检双轮驱动"战略，通过"团检公域引流，个检私域沉淀"的路径优化客户结构，2 5H 1个人客户占收入比提升至33%，2024 年全年该比例为24.1%。公司积极围绕重点学科布局，打造"筛查- 诊断-干预-管理"的完整健康管理闭环，引入GLP-1RA 等最新减重药物，截至三季度末公司开设33 家减 重代谢门诊，从体检筛查向下游的健康干预和慢病管理服务延伸，探索新的成长空间。 近期，公司分别合作精准诊疗与具身智能企业，通过打造" 体检中心+居家服务"双场景和"AI 主动健康 中心"，构建全周期健康管理模式。展望Q4 和明年，产品端，公司有望凭借专精特新产品（如心肺联 筛、AI-MDT、AI 智能肝健康、血液学时钟）以及与达摩院合作的"平扫CT+AI"胰腺癌筛查商业化，稳 定提升客单价；在拓客模式上，公司持续推动"团检公域引流、个检私域沉淀"，有助于提升体检旺季的 到检量、培育C 端客户粘性；在成本端，公司有望通过"健康小美"等管理工具提升体检效率，逐步释放 利润空间。 事件 2025 年12 月19 日，美年健康与精准诊疗领域龙头企业圣湘生物签署战略合作协议，双方将打造"体检 中心+居家 ...

Core Viewpoint - The article discusses the emergence of a new era in the anti-aging industry, driven by data and AI, as China enters a "super-aging" phase, with the market expected to exceed 4.6 trillion yuan by 2035. The key challenge has been supply, with a lack of standardized, low-threshold tools for consumers [1][4]. Demand Side - A "perfect storm" is forming on the demand side, driven by policies, demographics, and changing consumer mindsets. Policies are clearly directing the development of the anti-aging industry, while the younger demographic (ages 19-35) is becoming the main consumer group, accounting for 56.6% of anti-aging spending [4][5]. Supply Side - The traditional anti-aging sector has struggled with the challenge of measuring product value. Existing models like DNA methylation clocks and protein clocks are costly and limited in application, making it difficult to penetrate the mass market [5][6]. Technological Breakthrough - The launch of the "Hematological Clock" by Meinian Health represents a significant breakthrough, enabling the industry to transition from "concept consumption" to "data-driven" services. This product uses routine health check data to assess biological age, significantly lowering costs compared to high-end anti-aging tests [6][7]. Three Pillars of Capability - The "Hematological Clock" is built on three foundational capabilities: unprecedented data scale, non-linear algorithm philosophy, and self-evolving architecture. These elements create a strong competitive moat and long-term compounding effects [7][8][9]. Data Scale - Meinian Health's extensive real-world health data provides a robust training foundation for the "Hematological Clock," capturing aging trajectories across various demographics and lifestyles, which is crucial for precise assessments [8]. Non-linear Algorithms - The use of non-linear modeling allows the "Hematological Clock" to analyze the interrelationships between health indicators, identifying key factors driving aging, thus moving from correlation to causation [9][10]. Self-evolution - The product's architecture allows it to continuously improve its predictive capabilities based on user data, enhancing user engagement and increasing the platform's competitive edge over time [11]. Service Transformation - The "Hematological Clock" transforms the traditional health check into a long-term management service, addressing structural pain points in the industry. It creates a complete service loop of "detection-insight-intervention," allowing for personalized health management [12][15]. Revenue Models - The service offers diverse monetization opportunities, including standalone products for consumers and customized health management solutions for businesses, thus expanding the market reach [13][14]. Strategic Significance - The launch of the "Hematological Clock" marks a strategic milestone for Meinian Health, representing a shift from a single product to a sustainable profit ecosystem, crucial for growth in a competitive market [15].

Core Viewpoint - The launch of the "Hematological Clock" product by Meinian Health represents a significant step in the company's innovation strategy, aimed at enhancing its commercial competitiveness through AI-based biological age assessment using routine health check data [1][3]. Group 1: Product Launch and Development - Meinian Health introduced the "Hematological Clock" at a press conference in Shanghai, marking a key milestone in its innovation strategy [1]. - The product is designed to address the gap in traditional health check-ups, which primarily focus on disease screening rather than aging assessment and health span extension [3]. - The development of aging assessment technology has evolved over time, with the "Hematological Clock" being a culmination of years of research and collaboration with Fipeng Bio [3][4]. Group 2: Technical and Scientific Basis - The product leverages over 200 million health check data points, utilizing a dataset of 300,000 anonymized health check records across various demographics to build its predictive model [4][5]. - An innovative algorithm system was developed to extract "aging signals" from health check data, enabling accurate biological age predictions [5]. Group 3: Competitive Advantages - The "Hematological Clock" sets a new industry standard with its unique technical architecture, achieving a Pearson correlation coefficient of 0.896 between predicted biological age and actual age, with a mean absolute error of only 2.90 [6]. - The product is designed for accessibility, allowing users to upload routine health check reports without the need for additional tests, thus lowering barriers to anti-aging assessments [6][7]. Group 4: Target Audience and Market Potential - The target audience includes health-conscious young adults, practitioners of anti-aging interventions, individuals seeking quality longevity, and those at risk of chronic diseases [7]. - The product not only enhances consumer package offerings but also provides customized solutions for B2B clients, creating diverse revenue opportunities [7]. Group 5: Future Development Strategy - Meinian Health outlined a three-step strategy for future product development, focusing on optimizing the current "Hematological Clock," integrating multimodal data, and eventually launching a comprehensive "multi-omics digital health clock" [8][9]. - The long-term vision is to establish a one-stop service ecosystem for anti-aging that combines in-depth health checks, precise assessments, and personalized interventions [9].